Name: JAZZ PHARMACEUTICALS PLC (JAZZ) Stock
Brand: JAZZ PHARMACEUTICALS PLC
Rating: 7.5 (3 reviews)

JAZZ Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

4 days ago - By: Benzinga - Mentions: ALKS AVDL

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

6 days ago - By: Benzinga

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)

24 days ago - By: Jazz Pharmaceuticals plc

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

26 days ago - By: Zacks Investment Research - Mentions: ACAD AXSM

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

3 months ago - By: Stocktwits

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

a month ago - By: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

2 months ago - By: Zacks Investment Research - Mentions: ACAD AXSM

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

2 months ago - By: Yahoo Finance

Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355

2 months ago - By: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

2 months ago - By: Zacks Investment Research - Mentions: GSK ACAD

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

2 months ago - By: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

2 months ago - By: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

3 months ago - By: Zacks Investment Research

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

3 months ago - By: Jazz Pharmaceuticals

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

3 months ago - By: The Motley Fool

Jazz (JAZZ) Q2 Revenue Rises 2%

3 months ago - By: Zacks Investment Research - Mentions: CRMD GMAB IMCR

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

3 months ago - By: Zacks Investment Research

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

3 months ago - By: Zacks Investment Research - Mentions: IMNM

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

3 months ago - By: Zacks Investment Research - Mentions: CRMD AXSM IMCR

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

3 months ago - By: Yahoo Finance - Mentions: MS WFC

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock News

JAZZ Latest News, Press Relases and Analysis

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Jazz (JAZZ) Q2 Revenue Rises 2%

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating